Six U.S. senators sent letters to Reynolds American and Altria, questioning their lobbying and donations to the Trump administration. They allege these actions influenced the FDA's new 'enforcement discretion' policy for vapes and nicotine pouches, allowing companies to sell products without a license and leading to a 'lucrative payday'.
The senators' inquiry highlights concerns about the influence of corporate lobbying and political donations on regulatory policy, potentially impacting public health and the independence of regulatory agencies like the FDA.
Six U.S. senators, including Democratic whip Dick Durbin and Elizabeth Warren, have sent letters to tobacco companies Reynolds American and Altria. The senators are questioning the companies about political donations and lobbying efforts directed at the Trump administration. The letters state that these actions allowed tobacco makers to circumvent federal laws and sell addictive vapes, thereby harming the FDA's independence and providing the companies with a 'lucrative payday.'
This development follows the U.S. Food and Drug Administration's recent announcement of a new "enforcement discretion" policy. This policy permits certain manufacturers to sell vapes and nicotine pouches without the legally required license, a move that could lead to hundreds of new products entering the market. The policy shift also occurred after political donations from both Reynolds and Altria in April and a meeting between President Donald Trump and tobacco executives in May.
The senators' letters, dated June 4, express concern that these lobbying efforts and donations enabled tobacco companies to weaken federal tobacco oversight. The companies have previously complained about the booming market for unlicensed devices, estimated to be worth approximately £7 billion ($9.41 billion), and have engaged in lobbying campaigns and legal actions. Following the new FDA policy, tobacco companies have already announced plans to launch new products.